Garner Elizabeth 4

4 · Kezar Life Sciences, Inc. · Filed Jul 26, 2023

Form 4

Period: 2023-07-24

Director

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−17,793→ 0 total
Exercise: $3.03Exp: 2029-12-17→ Common Stock (17,793 underlying)
Award
Stock Option (Right to Buy)
2023-07-24+17,793→ 17,793 total
Exercise: $2.28Exp: 2029-12-17→ Common Stock (17,793 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−26,000→ 0 total
Exercise: $5.59Exp: 2031-06-27→ Common Stock (26,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−8,896→ 0 total
Exercise: $5.60Exp: 2030-06-23→ Common Stock (8,896 underlying)
Award
Stock Option (Right to Buy)
2023-07-24+8,896→ 8,896 total
Exercise: $2.28Exp: 2030-06-23→ Common Stock (8,896 underlying)
Award
Stock Option (Right to Buy)
2023-07-24+26,000→ 26,000 total
Exercise: $2.28Exp: 2031-06-27→ Common Stock (26,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2023-07-24−26,000→ 0 total
Exercise: $4.80Exp: 2032-06-15→ Common Stock (26,000 underlying)
Award
Stock Option (Right to Buy)
2023-07-24+26,000→ 26,000 total
Exercise: $2.28Exp: 2032-06-15→ Common Stock (26,000 underlying)

Footnotes (2)

[F1]Fully vested and exercisable.
[F2]On July 24, 2023, the option originally granted to the Reporting Person was amended to reduce the exercise price to $2.28 per share. All of the other terms of the option remain unchanged.

Documents

1 file